Clinical–Liver, Pancreas, and Biliary TractThe utility of radiological imaging in nonalcoholic fatty liver disease☆,☆☆
Section snippets
Patient selection
Consecutive patients with the clinicopathologic diagnosis of NAFLD were invited to participate in the study. After obtaining informed consent, we used the following criteria for patient enrollment: (1) persistently abnormal liver enzyme levels for more than 3 months, (2) findings on liver biopsy consistent with NAFLD according to a previously developed NAFLD pathologic protocol,19 (3) other causes of liver disease excluded (such as chronic viral hepatitis, autoimmune hepatitis, hemochromatosis,
Clinical, radiological, and pathologic associations
Twenty-five patients met the inclusion/exclusion criteria and consented to enroll in the study; 8 of these were categorized with steatosis and 17 with NASH. The 2 groups showed no differences in age, sex, body mass index, history of diabetes mellitus, or serum lipid levels. Patients with NASH had higher aspartate aminotransferase levels (P = 0.03), higher ferritin levels (P = 0.05), more hepatocyte ballooning (P < 0.0001), and more fibrosis (P = 0.002). Demographic, laboratory, and pathologic
Discussion
This is the largest and most in-depth study of patients with pathologically proven NAFLD in whom simultaneous radiological assessments with 3 different modalities were obtained shortly after liver biopsy. This study indicates that the severity of hepatic steatosis can be accurately determined radiologicalally only when there is moderate or severe (>33%) fatty infiltration of the liver documented by a liver biopsy. Although the role of US in assessing hepatic steatosis was reported in the 1980s,
References (35)
- et al.
Nonalcoholic fatty liver disease
Prog Liver Dis
(1986) - et al.
Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease
Mayo Clin Proc
(1980) Nonalcoholic steatohepatitis: tightening the morphological screws on a hepatic rambler
Hepatology
(1995)Non-alcoholic fatty liver disease: a review
Curr Gastroenterol Rep
(1999)- et al.
Review: nonalcoholic steatohepatitis
J Gastroenterol Hepatol
(1997) - et al.
Alcoholic disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury
Gastroenterology
(1988) - et al.
Nonalcoholic steatohepatitis: an expanded clinical entity
Gastroenterology
(1994) - et al.
The natural history of nonalcoholic fatty liver: a follow-up study
Hepatology
(1995) - et al.
Association of non-alcoholic fatty liver disease with insulin resistance
Am J Med
(1999) - et al.
Varying body mass index cut-off points to describe overweight prevalence among U.S. adults: NHANES 1988-1994
Obes Res
(1997)
Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors
Hepatology
Nonalcoholic steatohepatitis
Ann Intern Med
Fatty liver hepatitis and cirrhosis in obese patients
Am J Med
Nonalcoholic steatohepatitis in obesity: a reversible condition
Acta Med Scand
Hepatic morphology in obesity
Dig Dis Sci
Fatty liver disease in morbid obesity
Gastroenterol Clin North Am
Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese
Gastroenterology
Cited by (1699)
Detection of moderate hepatic steatosis on contrast-enhanced dual-source dual-energy CT: Role and accuracy of virtual non-contrast CT
2024, European Journal of RadiologyMetabolic dysfunction associated steatotic liver disease: Current practice, screening guidelines and management in the primary care setting
2024, American Journal of the Medical SciencesImpact of nonalcoholic fatty liver disease on the risk of gallbladder polyps in lean and non-obese individuals: A cohort study
2024, Hepatobiliary and Pancreatic Diseases InternationalUtility of ultrasonography in a mouse model of non-alcoholic steatohepatitis induced by a choline-deficient, high-fat diet and dextran sulfate sodium
2023, Biochemistry and Biophysics Reports
- ☆
Address requests for reprints to: Zobair M. Younossi, M.D., M.P.H., Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, Virginia 22042. e-mail: [email protected]; fax: (703) 698-3481.
- ☆☆
Supported in part by a grant from the Cleveland Clinic Hepatology Research Institute (to Z.M.Y.).